BioCentury
ARTICLE | Clinical News

NBI-6024: Began Phase I testing

March 22, 1999 8:00 AM UTC

Neurocrine Biosciences Inc. (NBIX), San Diego, Calif. Product: NBI-6024 Business: Metabolic Therapeutic category: Immune modulation Target: NA Description: Altered peptide ligand that down-regulates t...